SecBot SecBot
6-K ·Filed May 18, 2026

RDY

DR REDDYS LABORATORIES LTD
NEUTRAL
Impact 2/10
Horizonimmediate Processed6mo ago SEC0001575872-26-000339
Notable filing: 6-K
Actionable Insight • Neutral

This is a standard non-deal roadshow schedule with no material information. No trading action warranted. Monitor for any subsequent 6-K filings that may contain earnings results or business updates from these meetings.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$13.60
T+0 close · May 18, 2026 · via day close
Latest settled
−8.90%
T+60 · $12.39
Vs SPY
−13.75%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 18 $13.60entry
  2. T+1 · 6mo ago −1.10%α −0.45% · $13.45
  3. T+5 · 6mo ago +1.10%α −0.52% · $13.75
  4. T+20 · 5mo ago −2.21%α −3.79% · $13.30
  5. T+60 · 3mo ago −8.90%α −13.75% · $12.39

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dr. Reddy's Laboratories filed a 6-K furnishing a schedule of upcoming analyst/institutional investor meetings from May 20 to June 3, 2026, hosted by Elara Capital, Bank of America, Nomura, and Investec across Hong Kong, Singapore, Toronto, Boston, New York, and Princeton. This is a routine disclosure of non-deal roadshow activity with no material financial information, guidance, or operational updates.

Key Facts

  • Management will participate in investor meetings from May 20 to June 3, 2026
  • Meetings hosted by Elara Capital, Bank of America, Nomura, and Investec
  • All meetings are in-person group meetings across Hong Kong, Singapore, Toronto, Boston, New York, and Princeton
  • No financial results, guidance, or material business updates were disclosed

Financial Impact

No financial figures disclosed, routine investor relations activity with no quantifiable impact

Risk Factors

  • No material risks identified from this filing

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
50% bullish (44 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001575872-26-000339
Document: 0001575872-26-000339-index.html0001575872-26-000339
Document: 0001575872-26-000339.txt0001575872-26-000339

Track record

73 reports on RDY

Performance horizon

7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +23.28% at T+20 after the Jun 26, 2026 report. 7 of 12 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 Now $14.70 −1.01% settles Nov 23
  2. Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 Now $14.70 −1.08% settles Nov 17
  3. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 Now $14.70 −2.33% ▼ −2.33% −0.63% vs SPY
  4. Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 Now $14.70 +1.17% ▲ +1.38% −1.91% vs SPY
  5. Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 Now $14.70 −0.47% ▲ +0.47% +1.39% vs SPY
  6. Nov 2, 202614d ago 144 Bearish 5/10 Entry $14.13 to $15.05 Now $14.70 −4.03% ▼ −6.51% −6.43% vs SPY
  7. Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  8. Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  9. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
  10. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
Showing 10 of 73

US Market Status

Market Closed · Opens in 5h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 18, 2026